Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Horizon Completes Enrollment of Japan PIII for Thyroid Eye Disease Drug
Horizon Therapeutics said on November 16 that it has completed the enrollment of its PIII clinical trial in Japan to evaluate teprotumumab, known as Tepezza in the US, for the treatment of active thyroid eye disease (TED). The PIII trial,…
To read the full story
Related Article
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
- Horizon Taps Yoshihide Okino as VP and Japan GM
June 8, 2022
- Horizon Launches Japan PIII for Thyroid Eye Disease Drug
February 25, 2022
- Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
BUSINESS
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Astellas Starts Setidegrasib PIII in KRAS G12D-Mutated NSCLC
September 24, 2026
- Otsuka’s Antisense Drug Hits PIII Goal in FUS-ALS
September 24, 2026
- EU Panel Backs Enhertu for Adjuvant Use in HER2-Positive Breast Cancer
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…